Avadel pharmaceuticals announces data supporting clinical profile for lumryz™ at sleep 2023

– 12 accepted abstracts highlight company's emerging leadership in narcolepsy – – data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of once-at-bedtime lumryz – – company to support symposium on june 6 with leading kols discussing unmet needs in the advancement of narcolepsy treatment – dublin, may 31, 2023 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for lumryz™ (sodium oxybate) for extended-release oral suspension (ciii) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at sleep 2023, the 37th annual joint meeting of the american academy of sleep medicine and the sleep research society, being held from june 3-7, 2023 in indianapolis. lumryz (previously known as ft218), is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (eds) in adults with narcolepsy.
AVDL Ratings Summary
AVDL Quant Ranking